Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 4, Pages 353
Publisher
MDPI AG
Online
2021-03-30
DOI
10.3390/biomedicines9040353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- L-Selectin/CD62L Is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men
- (2020) Hannah K. Drescher et al. Cells
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes
- (2020) Athanasia K. Papazafiropoulou et al. CURRENT PHARMACEUTICAL DESIGN
- Glucagon Like Peptide-1 Receptor Agonists Alters Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model
- (2020) Taiyong Fang et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
- (2020) Kavita Jadhav et al. Frontiers in Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway
- (2019) Zhi Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding—A Review of Rodent Models
- (2019) Saioa Gómez-Zorita et al. Nutrients
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
- (2019) Liang Xu et al. BMJ Open Diabetes Research & Care
- Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
- (2018) Zobair M. Younossi et al. Clinics in Liver Disease
- Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
- (2018) Robert Martinez et al. DIABETES
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial
- (2018) Juan P. Frías et al. DIABETES OBESITY & METABOLISM
- The Gut Microbiome Profile in Obesity: A Systematic Review
- (2018) Olga Castaner et al. International Journal of Endocrinology
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
- (2018) Hisamitsu Ishihara et al. Diabetes Therapy
- Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
- (2018) Hisamitsu Ishihara et al. Diabetes Therapy
- Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH
- (2018) Geoff Farrell et al. HEPATOLOGY
- The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease
- (2018) Samarth Patel et al. HEPATOLOGY
- Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- (2018) Francesco Bifari et al. PHARMACOLOGICAL RESEARCH
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
- (2017) Fabiana de Faria Ghetti et al. EUROPEAN JOURNAL OF NUTRITION
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- Targeting hepatic macrophages to treat liver diseases
- (2017) Frank Tacke JOURNAL OF HEPATOLOGY
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls
- (2017) Benjamin Heidrich et al. LIVER INTERNATIONAL
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2017) Yajie Dong et al. Clinics and Research in Hepatology and Gastroenterology
- High-Salt Diet Has a Certain Impact on Protein Digestion and Gut Microbiota: A Sequencing and Proteome Combined Study
- (2017) Chao Wang et al. Frontiers in Microbiology
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children
- (2016) David E. Kleiner et al. Clinics in Liver Disease
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Distinctly altered gut microbiota in the progression of liver disease
- (2016) Guoxiang Xie et al. Oncotarget
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents
- (2015) Richard A. Byrd et al. ENDOCRINOLOGY
- Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development
- (2014) Chun-Meng Jiang WORLD JOURNAL OF GASTROENTEROLOGY
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Comparing the anterior nare bacterial community of two discrete human populations using Illumina amplicon sequencing
- (2013) Amélia Camarinha-Silva et al. ENVIRONMENTAL MICROBIOLOGY
- Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+T cells
- (2013) Matthias Hardtke-Wolenski et al. HEPATOLOGY
- Ribosomal Database Project: data and tools for high throughput rRNA analysis
- (2013) James R. Cole et al. NUCLEIC ACIDS RESEARCH
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started